Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Optimer's Dificid linked to faster resolution of diarrhoea compared to vancomycin

This article was originally published in Scrip

Executive Summary

A new analysis of the Phase III results has shown that patients treated with its oral antibiotic Dificid (fidaxomicin) saw a speedier resolution of diarrhoea and lower risk of death during the first 12 days of initiation of treatment compared to those treated with ViroPharma's Vancocin (vancomycin). This boosts the company's marketing collateral for Dificid: Earlier this year Optimer gained US approval of Dificid for Clostridium difficile-associated diarrhoea, with superiority language differentiating the medicine from vancomycin, the only other US approved therapy for C. difficile (, 1 June 2011).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts